Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial.

Wagg A, Khullar V, Michel MC, Oelke M, Darekar A, Bitoun CE.

Neurourol Urodyn. 2014 Jan;33(1):106-14. doi: 10.1002/nau.22383. Epub 2013 Mar 4.

PMID:
23460503
2.

Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.

Staskin D, Khullar V, Michel MC, Morrow JD, Sun F, Guan Z, Dmochowski R.

Neurourol Urodyn. 2011 Nov;30(8):1480-5. doi: 10.1002/nau.21099. Epub 2011 May 10.

PMID:
21560158
3.

Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.

DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.

Neurourol Urodyn. 2012 Nov;31(8):1258-65. doi: 10.1002/nau.22252. Epub 2012 Aug 20.

PMID:
22907761
4.

Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.

Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Darekar A, Bitoun CE, Weinstein D, Osterloh I.

J Am Geriatr Soc. 2013 Feb;61(2):185-93. doi: 10.1111/jgs.12088. Epub 2013 Jan 25.

PMID:
23350833
5.

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.

Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, Dragon E, Mangan E.

BJU Int. 2014 Sep;114(3):418-26. doi: 10.1111/bju.12678. Epub 2014 Jul 1.

6.

Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies.

Sand PK, Heesakkers J, Kraus SR, Carlsson M, Guan Z, Berriman S.

Drugs Aging. 2012 Feb 1;29(2):119-31. doi: 10.2165/11597970-000000000-00000.

PMID:
22276958
7.

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.

BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x.

8.

Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.

Dubeau CE, Kraus SR, Griebling TL, Newman DK, Wyman JF, Johnson TM 2nd, Ouslander JG, Sun F, Gong J, Bavendam T.

J Urol. 2014 Feb;191(2):395-404. doi: 10.1016/j.juro.2013.08.027. Epub 2013 Aug 21.

PMID:
23973522
9.

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.

Wagg A, Wyndaele JJ, Sieber P.

Am J Geriatr Pharmacother. 2006 Mar;4(1):14-24.

PMID:
16730617
10.

Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.

Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z.

BJU Int. 2012 Jun;109(12):1831-40. doi: 10.1111/j.1464-410X.2011.10624.x. Epub 2011 Oct 3.

11.

Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.

Kelleher CJ, Dmochowski RR, Berriman S, Kopp ZS, Carlsson M.

BJU Int. 2012 Aug;110(3):392-400. doi: 10.1111/j.1464-410X.2011.10774.x. Epub 2011 Nov 30.

12.

Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.

Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.

BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.

13.

Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.

Khullar V, Cardozo L, Kelleher CJ, Hall T, Ryan J, Ebel Bitoun C, Darekar A, Arumi D, Wagg A.

BJU Int. 2013 Oct;112(6):820-9. doi: 10.1111/bju.12006. Epub 2013 Mar 7.

14.

Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.

Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M.

Eur Urol. 2007 Oct;52(4):1204-12. Epub 2007 Jul 17. Erratum in: Eur Urol. 2008 Jun;53(6):1319.

PMID:
17651893
15.

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.

Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.

PMID:
23608668
16.

Comparison of fesoterodine and tolterodine in patients with overactive bladder.

Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.

BJU Int. 2008 Nov;102(9):1128-32. doi: 10.1111/j.1464-410X.2008.07907.x. Epub 2008 Jul 21.

17.

Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation.

Cardozo L, Hall T, Ryan J, Ebel Bitoun C, Kausar I, Darekar A, Wagg A.

Int Urogynecol J. 2012 Nov;23(11):1581-90. doi: 10.1007/s00192-012-1804-1. Epub 2012 May 11.

PMID:
22576329
18.

Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms.

Van Kerrebroeck PE, Heesakkers J, Berriman S, Padmanabhan Aiyer L, Carlsson M, Guan Z.

Int J Clin Pract. 2010 Apr;64(5):584-93. doi: 10.1111/j.1742-1241.2010.02361.x. Epub 2010 Feb 19.

PMID:
20201992
19.

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C.

Eur Urol. 2013 Feb;63(2):283-95. doi: 10.1016/j.eururo.2012.10.016. Epub 2012 Nov 6.

PMID:
23182126
20.

Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.

Nitti VW, Rovner ES, Bavendam T.

BJU Int. 2010 May;105(9):1268-75. doi: 10.1111/j.1464-410X.2009.09037.x. Epub 2009 Nov 4.

Supplemental Content

Support Center